Rituximab as monotherapy and in addition to reduced chop in children with primary immunodeficiency and non-hodgkin lymphoma

Keyphrases

• Monotherapy 100%
• Non-Hodgkin Lymphoma 100%
• Rituximab 100%
• Primary Immunodeficiency 100%
• Cytotoxic Effect 33%
• CHOP Regimen 33%
• Chemotherapy 33%
• Complete Remission 33%
• Diffuse Large B-cell Lymphoma (DLBCL) 33%
• Ataxia Telangiectasia 33%
• Conventional Chemotherapy 33%
• Chromosome Breakage 33%
• Chemotherapy Regimen 33%
• Common Variable Immunodeficiency 33%
• First-line Monotherapy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Immune Deficiency 100%
• Nonhodgkin Lymphoma 100%
• Rituximab 100%
• Monotherapy 100%
• Chemotherapy 33%
• Remission 33%
• Syndrome 33%
• Diffuse Large B Cell Lymphoma 33%
• Chemotherapy Regimens 33%
• Chromosome Breakage 33%
• Ataxia Telangiectasia 33%
• Common Variable Immunodeficiency 33%

Immunology and Microbiology

• Immunodeficiency 100%
• Rituximab 100%
• B Cell 33%
• Cytotoxicity 33%
• Ataxia Telangiectasia 33%
• Chromosome Breakage 33%
• Common Variable Immunodeficiency 33%